



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: M. EISENBACH-SCHWARTZ

Application No.: 06/765,301

Conf. No. 8567

Filed: January 22, 2001

For: USE OF COPOLYMER 1 AND RELATED PEPTIDES AND POLYPEPTIDES AND ...

Art Unit: 1647

Examiner: B. Bunner

Washington, D.C.

Atty.'s Docket: EIS-SCHWARTZ=18

Date: January 23, 2003

TECH CENTER 1600/2900

JAN 28 2003

RECEIVED

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a ☒ Amendment ☒ Kipnis Journal Article
in the above-identified application.☒ Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.☐ No additional fee is required.☒ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 46	MINUS	** 42	0
INDEP.	* 3	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
\$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
\$	

OR

OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☒ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

☐ First - \$ 55.00☐ Second - \$ 205.00☒ Third - \$ 465.00☐ Fourth - \$ 725.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

☐ First - \$ 110.00☐ Second - \$ 410.00☐ Third - \$ 930.00☐ Fourth - \$ 1450.00


Month After Time Period Set

☐ Less fees (\$) already paid for month(s) extension of time on .☐ Please charge my Deposit Account No. 02-4035 in the amount of \$.☒ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$ 465.00.☐ A check in the amount of \$ is attached (check no.).☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

Facsimile: (202) 737-3528
Telephone: (202) 628-5197By: Roger L. Browdy
Roger L. Browdy
Registration No. 25,618by Allen Yun
Reg. No. 37,971



#12/B
DmT
2-10-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ=18

In re Application of:)	Conf. No.: 8567
)	
M. EISENBACH-SCHWARTZ et al)	Art Unit: 1647
)	
Appln. No.: 09/765,301)	Examiner: B. Bunner
)	
Filed: January 22, 2001)	Washington, D.C.
)	
For: USE OF COPOLYMER 1 AND)	January 23, 2003
RELATED PEPTIDES AND)	
POLYPEPTIDES FOR ...)	

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of July 30, 2002,
petition for a three-month extension of time and payment being
attached hereto, please amend as follows:

IN THE SPECIFICATION

Replace the paragraph beginning at page 55, line 10,
with the following rewritten paragraph:

B1 In another embodiment, mononuclear phagocyte cells
according to PCT Publication No. WO 97/09985 and U.S. patent
no. 6,267,955 are injected into the site of injury or lesion
within the CNS, either concurrently, prior to, or following

01/24/2003 SZEHDIE1 00000067 09765301

01 FC:2253

465.00 OP

RECEIVED
JAN 28 2003
TECH CENTER 1600/2900